Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | IL17A | Q16552 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 10/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 9/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298409 | 0.89 | SRC (0.43) | SRCEGFRKDR | |
| SCHEMBL4299761 | 0.88 | SCD (0.34) | EGFRPARP1DRD2KCNH2CACNA1I | |
| SCHEMBL3275698 | 0.84 | SRC (0.51) | BRD4IL17ASRCEGFRKDR | |
| SCHEMBL3282183 | 0.80 | PDE4B (0.46) | EGFR | |
| SCHEMBL3282936 | 0.80 | ALDH1A1 (0.41) | BRD4IL17ASRCEGFR | |
| SCHEMBL1015994 | 0.77 | EGFR (0.48) | SRCEGFRKDR | |
| SCHEMBL16747789 | 0.76 | SRC (0.49) | SRCEGFRKDR | |
| SCHEMBL4266694 | 0.76 | SRC (0.53) | SRCEGFRKDR | |
| SCHEMBL16742334 | 0.75 | SRC (0.53) | BRD4IL17ASRCEGFRKDR | |
| SCHEMBL3195404 | 0.74 | SRC (0.47) | SRCEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | BRD4 726/4885IL17A 4030/4885SRC 785/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | BRD4 557/4885IL17A 4054/4885SRC 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.